At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 13, 2026 at 08:00 ET
Lifeward announced shareholder approval of a strategic partnership with Oramed Pharmaceuticals, integrating Oramed’s POD™ oral delivery technology into Lifeward’s platform while receiving potential access to up to $47 million in capital. Oramed will fund clinical development of the biotech platform, allowing Lifeward to maintain focus on its core MedTech business and path to profitability.
- Shareholders approved the issuance of shares related to the strategic partnership with Oramed Pharmaceuticals (Nasdaq: ORMP).
- Lifeward gains access to Oramed’s POD™ oral delivery technology for biologics, with potential applications in diabetes and other chronic diseases.
- Oramed will fund and manage the clinical development of the POD™ platform under a trial management agreement.
- Lifeward could receive up to $47 million in capital via equity, convertible notes, milestone payments, and warrants from Oramed and another investor.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access